Third Quarter 2026
Filed Nov 4, 2026Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported expanded Phase 2a bempikibart efficacy and off-drug durability data, raised approximately $200.0 million in gross offering proceeds during July, and ended the quarter with $289.6 million of cash and cash equivalents. The quarter’s net loss increased to $8.9 million from $7.4 million as bempikibart clinical, manufacturing and ADX-914-XL preclinical costs increased.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30GAAP | $5.15M | – | – |
| General and administrative expenses, three months ended September 30GAAP | $5.51M | – | – |
| Total operating expenses, three months ended September 30GAAP | $10.66M | – | – |
| Loss from operations, three months ended September 30GAAP | −$10.66M | – | – |
| Other income, net, three months ended September 30GAAP | $1.74M | – | – |
| Total other income, three months ended September 30GAAP | $1.74M | – | – |
| Net loss and comprehensive loss, three months ended September 30GAAP | −$8.92M | – | – |
| Net loss per share—basic and diluted, three months ended September 30GAAP | $ (0.26 ) | – | – |
| Weighted-average common shares—basic and diluted, three months ended September 30GAAP | 34,022,755 | – | – |
| Research and development expenses, nine months ended September 30GAAP | $12.63M | – | – |
| General and administrative expenses, nine months ended September 30GAAP | $14.87M | – | – |
| Total operating expenses, nine months ended September 30GAAP | $27.5M | – | – |
| Loss from operations, nine months ended September 30GAAP | −$27.5M | – | – |
| Loss on extinguishment of debt, nine months ended September 30GAAP | $ (147 ) | – | – |
| Other income, net, nine months ended September 30GAAP | $2.17M | – | – |
| Total other income, nine months ended September 30GAAP | $2.02M | – | – |
| Net loss and comprehensive loss, nine months ended September 30GAAP | −$25.48M | – | – |
| Net loss per share—basic and diluted, nine months ended September 30GAAP | $ (1.11 ) | – | – |
| Weighted-average common shares—basic and diluted, nine months ended September 30GAAP | 22,912,875 | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $289.6M | – | – |
| Right-of-use asset, operating leases, September 30, 2026GAAP | 4,601 | – | – |
| Restricted cash and restricted cash equivalents, September 30, 2026GAAP | 647 | – | – |
| Other assets, September 30, 2026GAAP | 2,366 | – | – |
| Total assets, September 30, 2026GAAP | $297.2M | – | – |
| Accounts payable, accrued expenses and other current liabilities, September 30, 2026GAAP | $5.17M | – | – |
| Lease liability, net of current portion, September 30, 2026GAAP | 4,364 | – | – |
| Venture debt, September 30, 2026GAAP | — | – | – |
| Stockholders’ equity, September 30, 2026GAAP | 287,670 | – | – |
| Total liabilities and stockholders’ equity, September 30, 2026GAAP | $297.2M | – | – |
Through topline Phase 3 results from planned registration-directed program; second half of 2027; first half of 2027 outlook
- NoteCash and cash equivalents as of September 30, 2026 are sufficient to fund operations through topline Phase 3 results from its planned registration-directed program evaluating bempikibart in patients with severe or very severe AA.
- NoteQ32 Bio anticipates data from the Part B OLE in the second half of 2027.
- NoteQ32 Bio plans to advance bempikibart into a registration-directed program for patients with severe or very severe AA in the first half of 2027 subject to planned regulatory discussions in the fourth quarter of 2026.
Capital returns
- In July 2026, Q32 Bio completed a public offering of common stock and pre-funded warrants, raising gross proceeds of approximately $200.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Q32 Bio.
What drove it
- In Part B at Week 36, bempikibart demonstrated a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis.
- 40.0% of patients achieved a SALT-20 response at Week 36 in the mITT analysis, while 30.3% achieved a SALT-20 response at Week 36 in the ITT analysis of all enrolled patients.
- Research and development expense increased primarily due to higher bempikibart clinical and manufacturing costs and preclinical development costs for ADX-914-XL.
- General and administrative expense increased primarily due to higher stock-based compensation expense and other employee-related costs.
- The 16-week off-drug follow-up period showed maintenance and deepening of response, according to the company.
Concerns
- The planned registration-directed program is subject to planned regulatory discussions in the fourth quarter of 2026.
- The Part B OLE remains ongoing, with data anticipated in the second half of 2027.
- Net loss and comprehensive loss was $ (8,922 ) for the three months ended September 30, 2026, versus $ (7,389 ) for the prior-year period.
- The company states that additional data or ongoing data analyses may not support its current beliefs and expectations for bempikibart, including durability of clinical responses.
- The company states it may use capital resources sooner than currently anticipated and may need additional funding to complete clinical studies.
What to watch
- Planned regulatory discussions in the fourth quarter of 2026.
- Initiation of the registration-directed bempikibart program in the first half of 2027.
- Part B OLE data expected in the second half of 2027.
- Future study evaluation of monthly, bi-monthly or quarterly chronic maintenance dosing.
- Progress of ADX-914-XL, which continues in preclinical development.
Balance sheet and cash flow
- Cash and cash equivalents were $289.6 million as of September 30, 2026.
- Cash and cash equivalents were $ 289,587 as of September 30, 2026, compared with $ 48,297 as of December 31, 2025.
- Restricted cash and restricted cash equivalents were 647 as of September 30, 2026 and 647 as of December 31, 2025.
- Venture debt was — as of September 30, 2026, compared with 9,708 as of December 31, 2025.
- Total assets were $ 297,201 as of September 30, 2026, compared with $ 61,776 as of December 31, 2025.
- Stockholders’ equity was 287,670 as of September 30, 2026, compared with 42,014 as of December 31, 2025.
Analysis
Q32 Bio’s third-quarter update was led by additional Phase 2a SIGNAL-AA Part B data rather than commercial activity. At Week 36, the company reported a 35.3% mean percent reduction in SALT score from baseline in the prespecified mITT analysis. It also reported SALT-20 responses in 40.0% of mITT patients and 30.3% of all enrolled patients in the ITT analysis. The company said responses were maintained or deepened during the 16-week off-drug follow-up period, while bempikibart was generally well-tolerated with no new safety signals.
Operating costs increased in the quarter. Research and development expense was $ 5,149 versus $ 3,555 in the prior-year quarter, driven primarily by higher bempikibart clinical and manufacturing costs and ADX-914-XL preclinical development costs. General and administrative expense was $ 5,511 versus $ 4,022, reflecting higher stock-based compensation and other employee-related costs. Total operating expenses were $ 10,660, and loss from operations was $ (10,660 ).
Net loss and comprehensive loss was $ (8,922 ), or $ (0.26 ) per basic and diluted share, compared with $ (7,389 ), or $ (0.60 ) per basic and diluted share, in the prior-year quarter. Other income, net was $ 1,738 versus $ 188, which reduced the reported net loss relative to the operating loss. For the nine months ended September 30, total operating expenses were $ 27,500 versus $ 28,977, while net loss and comprehensive loss was $ (25,477 ) versus $ (27,909 ).
Liquidity increased materially following the July public offering of common stock and pre-funded warrants, which generated gross proceeds of approximately $200.0 million before underwriting discounts, commissions and offering expenses. Cash and cash equivalents were $289.6 million as of September 30, 2026, compared with $ 48,297 at December 31, 2025. Venture debt was — at September 30, 2026, compared with 9,708 at December 31, 2025. Management states that cash and cash equivalents are sufficient to fund operations through topline Phase 3 results from the planned registration-directed program.
The near-term operating focus is regulatory and clinical execution. The company plans to initiate a registration-directed program in severe or very severe AA in the first half of 2027, subject to regulatory discussions planned for the fourth quarter of 2026. The Part B OLE is ongoing, with data anticipated in the second half of 2027, and is intended to inform long-term maintenance regimens that could include monthly, bi-monthly or quarterly dosing. The timing of regulatory discussions, registration-directed program initiation and OLE data are the principal disclosed milestones.
Management, verbatim
The third quarter brought continued momentum for Q32 Bio and our bempikibart program. We shared encouraging SIGNAL-AA Part B results in late-breaking oral and poster presentations at EADV, highlighting bempikibart’s clinically meaningful efficacy data at Week 36 and ability to induce durable responses that were maintained or deepened through the 16-week off-drug period, supporting the potential for less frequent, chronic maintenance dosing.
Jodie Morrison, Chief Executive Officer of Q32 Bio
With a strong balance sheet, we believe we are well positioned to rapidly advance into a registration-directed program in severe or very severe alopecia areata in the first half of 2027 following planned regulatory discussions this quarter, as well as in other autoimmune and inflammatory indications.
Jodie Morrison, Chief Executive Officer of Q32 Bio
Not in the filing
stated, not guessed- Revenue was not reported.
- Segment revenue and segment operating metrics were not reported.
- Gross profit and gross margin were not reported.
- Non-GAAP financial measures were not reported.
- Operating cash flow and free cash flow were not reported.
- Dividend and share-repurchase activity were not reported.
- A quantitative revenue, gross margin, operating expense or tax-rate outlook was not reported.
- Prior-quarter comparisons for reported operating metrics were not reported.
- A previous outlook section was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.